Literature DB >> 16881862

Not-so-sweet sixteen: the role of IL-16 in infectious and immune-mediated inflammatory diseases.

William G Glass1, Robert T Sarisky, Alfred M Del Vecchio.   

Abstract

Over the past two decades, our understanding of interleukin-16 (IL-16) has increased substantially. Initial studies characterizing IL-16 as a chemotactic cytokine (but not a chemokine) just scratched the surface of the unique properties of this cytokine. Since then, scientists have determined that IL-16 has a wide range of effects on cells, including upregulation of CD25, induction of cells to progress to the G(1) phase, inhibition of antigen- specific proliferation yet with retained antigen nonspecific proliferative properties, and discovery of a novel neuronal form with unique properties. Recently, a plethora of studies have implicated IL-16 in exacerbation of infectious, immune-mediated, and autoimmune inflammatory disorders, including atopic dermatitis, irritable bowel syndrome, systemic lupus erythematosus, neurodegenerative disorders, and viral infections. Herein, we review the body of evidence supporting a role for IL-16 in infectious and immune-mediated inflammatory disorders and explore the known and possible mechanism of actions in the numerous diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16881862     DOI: 10.1089/jir.2006.26.511

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  27 in total

Review 1.  T-cell positioning by chemokines in autoimmune skin diseases.

Authors:  Jillian M Richmond; James P Strassner; Kingsley I Essien; John E Harris
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

2.  Down-regulation of interleukin-16 in human mast cells HMC-1 by Clostridium difficile toxins A and B.

Authors:  Ralf Gerhard; Swenja Queisser; Helma Tatge; Gesa Meyer; Oliver Dittrich-Breiholz; Michael Kracht; Hanping Feng; Ingo Just
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-01-26       Impact factor: 3.000

3.  Gene expression changes in multiple sclerosis relapse suggest activation of T and non-T cells.

Authors:  J William Lindsey; Sandeep K Agarwal; Filemon K Tan
Journal:  Mol Med       Date:  2010-09-17       Impact factor: 6.354

Review 4.  [Genetics of contact allergy].

Authors:  A Schnuch
Journal:  Hautarzt       Date:  2011-10       Impact factor: 0.751

5.  Downregulated interleukin 37 expression associated with aggravation of intervertebral disc degeneration.

Authors:  Zhong-Yuan Wan; Zhen Sun; Fang Song; Yu-Fei Chen; Wei-Lin Zhang; Hai-Qiang Wang; Zhuo-Jing Luo
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

6.  Critical role of PBEF expression in pulmonary cell inflammation and permeability.

Authors:  Peng Liu; Hailong Li; Javier Cepeda; Li Qin Zhang; Xiuyun Cui; Joe G N Garcia; Shui Qing Ye
Journal:  Cell Biol Int       Date:  2008-11-01       Impact factor: 3.612

7.  Elevated IL-16 expression is associated with development of immune dysfunction in children with autism.

Authors:  Sheikh F Ahmad; Mushtaq A Ansari; Ahmed Nadeem; Saleh A Bakheet; Laila Y Al-Ayadhi; Sabry M Attia
Journal:  Psychopharmacology (Berl)       Date:  2018-11-19       Impact factor: 4.530

8.  Fine-mapping of IL16 gene and prostate cancer risk in African Americans.

Authors:  Ken Batai; Ebony Shah; Adam B Murphy; Jennifer Newsome; Maria Ruden; Chiledum Ahaghotu; Rick A Kittles
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-08-24       Impact factor: 4.254

9.  Gene expression changes in peripheral blood mononuclear cells during measles virus infection.

Authors:  Michael J Zilliox; William J Moss; Diane E Griffin
Journal:  Clin Vaccine Immunol       Date:  2007-05-30

10.  The Expression of Murine Double Minute 2 (MDM2) on Helicobacter pylori-Infected Intestinal Metaplasia and Gastric Cancer.

Authors:  Noriko Nakajima; Yoko Ito; Kiyoshi Yokoyama; Akitake Uno; Noriko Kinukawa; Norimichi Nemoto; Mitsuhiko Moriyama
Journal:  J Clin Biochem Nutr       Date:  2009-02-28       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.